Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lung Cancer Oncologists (US)

November 23, 2007
Revlimid plus Decadron beats Decadron alone in Multiple Myeloma. Go figure??
By a GLG Expert Contributor
Analysis of: Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma (content.nejm.org)
A study using Dexamethazone (Decadron) plus placebo as a control in a second line setting in multiple myeloma done outside the US. Are we surprised?
November 22, 2007
Erbitux, an alternative to Avastin in SOME metastatic colorectal carcinoma patients.
By a GLG Expert Contributor
Analysis of: Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer (jco.ascopubs.org)
Erbitux with FOLFOX 4 chemo is effective in MCRC. Not a surprise!
November 21, 2007
Avastin for Glioblastomas (GBM)- It's Time Has Come?
By a GLG Expert Contributor
Analysis of: Avastin Shows Encouraging Results in Phase II Study in Patients With the Most Aggressive Form of Brain Cancer (www.pipelinereview.com)
Avastin (Genentech), with or without Irinotecan (Pfizer), has activity in GBM's that have previously only been effectively treated with Temodar (Schering).
November 20, 2007
Avastin in Kidney Cancer? Yes but.....
By a GLG Expert Contributor
Analysis of: Avastin receives positive opinion in Europe for first-line treatment of patients with advanced kidney cancer (www.pipelinereview.com)
Avastin + interferon was better than interferon alone in kidney cancer as far as progression free survival was concerned.
November 19, 2007
Celgene buying Pharmion? Synergy??!!
By a GLG Expert Contributor
Analysis of: Celgene to Acquire Pharmion For $2.9 Billion in Cash, Stock (online.wsj.com)
This will establish Celgene as the ultimate in providing drugs for MDS and will push MGI's Dacogen to the rear. Other drugs in Parmions pipeline are just icing on the cake.
November 19, 2007
Breast Cancer, Lung cancer Cancer of the...... Pharmacogenomics should control our choices
By a GLG Expert Contributor
Analysis of: Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes (jco.ascopubs.org)
This breast cancer paper along with http://jco.ascopubs.org/cgi/content/full/25/33/5233 on lung cancer as well as an accompanying editorial http://jco.ascopubs.org/cgi/content/full/25/33/5147 on the first paper stress what I have been preaching pharmacogenetics is here!!! and must be considered in future...
November 16, 2007
Perifosine (AEterna Zentaris) Trial in Lung Cancer. What Will It Answer???
By a GLG Expert Contributor
Analysis of: AEterna Zentaris Announces Completion of Patient Enrollment for Multi-Center Phase 2 Trial with Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer (www.pipelinereview.com)
AEterna Zentaris Announces Completion of Patient Enrollment for Multi-Center Phase 2 Trial with Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer (NSCLCA)
November 16, 2007
Avax Phase III Trial: Headed in the right direction.....
By a GLG Expert Contributor
Analysis of: Avax initiates Phase III registration trial for metastasis vaccine (www.therapeuticsdaily.com)
Phase III "registration trial" to see if M-Vax, a tumor vaccine, will be effective in metastatic melanoma.
November 16, 2007
R84, an anti-VEGF antibody
By a GLG Expert Contributor
Analysis of: New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models (www.pipelinereview.com)
Potential competitor for Avastin??
November 14, 2007
Zevalin (Bayer) a great agent in lymphomas that will NOT be used because......
By a GLG Expert Contributor
Analysis of: Major Phase 3 Trial Shows Zevalin(R) Extends Progression-Free Survival in one of the most common types of Lymphoma (www.pipelinereview.com)
Zevalin can produce a lengthened remission in patients with low grade non Hodgkin's (follicular) lymphomas (LGNHL)

Previous Page : 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 Next231 to 240 of 457

Analytics


Generated at 2009-01-07T19:00:58.307